Engraftment of various numbers of human marrow CD34+ cells treated with 5azaD and TSA in NOD/SCID mice
Cell dose injected . | Primary CD34+ (95)* . | Cytokines alone (2.9)† . | Cytokines plus 5azaD/TSA (56.4)‡ . |
|---|---|---|---|
| 1 × 106 | 2/2 | 0/3 | 1/2 |
| 1 × 105 | 3/3 | NA | 1/3 |
| 1 × 104 | 1/3 | 0/3 | 0/3 |
| 1 × 103 | 0/3 | NA | 0/3 |
| 1 × 102 | 0/3 | NA | 0/3 |
Cell dose injected . | Primary CD34+ (95)* . | Cytokines alone (2.9)† . | Cytokines plus 5azaD/TSA (56.4)‡ . |
|---|---|---|---|
| 1 × 106 | 2/2 | 0/3 | 1/2 |
| 1 × 105 | 3/3 | NA | 1/3 |
| 1 × 104 | 1/3 | 0/3 | 0/3 |
| 1 × 103 | 0/3 | NA | 0/3 |
| 1 × 102 | 0/3 | NA | 0/3 |
This table shows the marrow repopulating potential of various doses plus cells injected from 3 different conditions. Numbers in parentheses indicate the percentage of CD34+ cells in the population injected at each dose. Data represent number of mice engrafted/total number of mice injected. Individual mice were scored as positive only when the number of human (CD45+) cells present 6 to 8 weeks after transplantation constituted ≥ 0.1% of the total marrow population by flow cytometry. NA indicates not available.
Primary CD34+ cells represent a pretreatment control, not cultured
Untreated CD34+ marrow cells, cytokines alone, were cultured for 9 days
5azaD- and TSA-treated cells were cultured for 9 days